MA49127A - Dérivés d'indole n-substitués - Google Patents
Dérivés d'indole n-substituésInfo
- Publication number
- MA49127A MA49127A MA049127A MA49127A MA49127A MA 49127 A MA49127 A MA 49127A MA 049127 A MA049127 A MA 049127A MA 49127 A MA49127 A MA 49127A MA 49127 A MA49127 A MA 49127A
- Authority
- MA
- Morocco
- Prior art keywords
- indole derivatives
- substituted indole
- substituted
- derivatives
- indole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2017062008 | 2017-05-18 | ||
PCT/EP2018/062865 WO2018210995A1 (fr) | 2017-05-18 | 2018-05-17 | Dérivés d'indole n-substitués |
Publications (2)
Publication Number | Publication Date |
---|---|
MA49127A true MA49127A (fr) | 2021-05-26 |
MA49127B1 MA49127B1 (fr) | 2022-05-31 |
Family
ID=62186481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49127A MA49127B1 (fr) | 2017-05-18 | 2018-05-17 | Dérivés d'indole n-substitués |
Country Status (32)
Country | Link |
---|---|
US (2) | US20200069686A1 (fr) |
EP (1) | EP3625224B1 (fr) |
JP (1) | JP7065117B2 (fr) |
KR (1) | KR102650756B1 (fr) |
CN (1) | CN110621666A (fr) |
AR (1) | AR111806A1 (fr) |
AU (1) | AU2018269667B2 (fr) |
BR (1) | BR112019024114A2 (fr) |
CA (1) | CA3063637A1 (fr) |
CL (1) | CL2019003257A1 (fr) |
CO (1) | CO2019010804A2 (fr) |
CR (1) | CR20190567A (fr) |
CY (1) | CY1124528T1 (fr) |
DK (1) | DK3625224T3 (fr) |
EA (1) | EA039630B1 (fr) |
ES (1) | ES2894124T3 (fr) |
HR (1) | HRP20211532T1 (fr) |
HU (1) | HUE056406T2 (fr) |
IL (1) | IL270616B (fr) |
LT (1) | LT3625224T (fr) |
MA (1) | MA49127B1 (fr) |
MX (1) | MX2019013639A (fr) |
PE (1) | PE20191787A1 (fr) |
PH (1) | PH12019502562A1 (fr) |
PL (1) | PL3625224T3 (fr) |
PT (1) | PT3625224T (fr) |
RS (1) | RS62441B1 (fr) |
SG (1) | SG11201908660RA (fr) |
SI (1) | SI3625224T1 (fr) |
TW (1) | TWI768043B (fr) |
UA (1) | UA124748C2 (fr) |
WO (1) | WO2018210995A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
US11446298B2 (en) | 2017-05-18 | 2022-09-20 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
WO2021060281A1 (fr) * | 2019-09-24 | 2021-04-01 | Agc株式会社 | Antagoniste double des récepteurs ep2/ep4 de la prostaglandine e2 |
CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1267867T3 (da) | 2000-03-24 | 2008-08-25 | Asterand Uk Ltd | Anvendelse af prostanoid-EP4-receptorantagonister til behandling af hovedpine og assays til sådanne antagonister |
HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
EP1494667A1 (fr) | 2002-04-12 | 2005-01-12 | Pfizer Japan Inc. | Composes imidazole servant d'agents anti-inflammatoires et analgesiques |
CA2482382A1 (fr) | 2002-04-12 | 2003-10-23 | Pfizer Inc. | Composes de pyrazole en tant qu'agents anti-inflammatoires et analgesiques |
BR0311247A (pt) | 2002-05-23 | 2005-03-15 | Theratechnologies Inc | Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2 |
ATE396182T1 (de) | 2003-01-29 | 2008-06-15 | Asterand Uk Ltd | Hemmstoffe des ep4-rezeptors |
EP1661897B1 (fr) * | 2003-08-26 | 2013-12-04 | Teijin Pharma Limited | Derive de pyrrolopyrimidinone |
ES2441206T3 (es) | 2003-09-03 | 2014-02-03 | Raqualia Pharma Inc. | Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2 |
GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
EA200601830A1 (ru) | 2004-05-04 | 2007-04-27 | Пфайзер Инк. | Ортозамещённые арильные или гетероарильные амидные соединения |
KR20070006891A (ko) | 2004-05-04 | 2007-01-11 | 화이자 인코포레이티드 | 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물 |
HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
EP1885722B1 (fr) | 2005-05-19 | 2011-11-16 | Merck Canada Inc. | Derives de quinoleine a titre d'antagonistes de ep4 |
WO2006128129A2 (fr) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Traitement anticancereux |
EP2013169B1 (fr) | 2006-04-24 | 2012-08-22 | Merck Canada Inc. | Dérivés d'indolamide comme antagonistes du récepteur ep4 |
EP2035376B1 (fr) | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Dérivés amide de l'indoline en tant que ligands du récepteur ep4 |
WO2008008059A1 (fr) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Agents anti-cancer et leurs utilisations |
WO2008006583A1 (fr) | 2006-07-14 | 2008-01-17 | Novartis Ag | Dérivés de la pyrimidine en tant qu'inhibiteurs d'alk-5 |
JP5259592B2 (ja) | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ep4受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
WO2008039882A1 (fr) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | Combinaison de niacine et d'un antagoniste du récepteur de prostaglandine d2 |
AU2008221194B2 (en) | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
US8003661B2 (en) | 2007-03-26 | 2011-08-23 | Merck Canada Inc. | Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists |
US8030489B2 (en) | 2007-03-26 | 2011-10-04 | Astellas Pharma Inc. | Ornithine derivative |
EP2014657A1 (fr) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine en tant que modulateurs du récepteur EP2 |
EP2460787A1 (fr) | 2007-07-03 | 2012-06-06 | Astellas Pharma Inc. | Composés d'amide et leur utilidsation comme anagonistes de la PGE2. |
CA2724077C (fr) | 2008-05-14 | 2016-04-26 | Astellas Pharma Inc. | Compose amide |
JP5536773B2 (ja) | 2008-08-14 | 2014-07-02 | ベータ・ファーマ・カナダ・インコーポレイテッド | Ep4受容体アンタゴニストとしてのヘテロ環式アミド誘導体 |
GB2474813B (en) | 2008-09-19 | 2014-05-28 | Biotechnology Res Corp Ltd | Triterpenoid compounds and methods of use thereof |
EP2346866B1 (fr) | 2008-09-25 | 2013-11-27 | Merck Canada Inc. | Dérivés de bêta-carboline sulfonylurée en tant qu antagonistes du récepteur d ep4 |
US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
EP3061751A1 (fr) | 2010-09-21 | 2016-08-31 | Eisai R&D Management Co., Ltd. | Composition pharmaceutique |
KR101857310B1 (ko) | 2010-09-29 | 2018-05-11 | 가부시키가이샤 에누비 켄코우겡큐쇼 | 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체 |
US8828987B2 (en) | 2010-12-10 | 2014-09-09 | Rottapharm Biotech S.R.L. | Pyridine amide derivatives as EP4 receptor antagonists |
WO2012103071A2 (fr) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Composés et compositions |
WO2012127032A1 (fr) * | 2011-03-24 | 2012-09-27 | Chemilia Ab | Nouveaux dérivés de pyrimidine |
ES2559513T3 (es) | 2011-07-04 | 2016-02-12 | Rottapharm Biotech S.R.L. | Derivados de amina cíclica como antagonistas del receptor EP4 |
EP2554662A1 (fr) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Procédés pour le traitement de maladies rétiniennes dégénératives |
WO2013090552A1 (fr) | 2011-12-13 | 2013-06-20 | Yale University | Compositions et procédés pour la réduction de l'épuisement de ctl |
RU2638540C1 (ru) | 2012-04-24 | 2017-12-14 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы днк-пк |
AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基-苯甲酸化合物 |
UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
EP2765128A1 (fr) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Benzamides substitués présentant une activité vis-à-vis de récepteurs EP4 |
TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫-1h-異喹啉化合物 |
US9593081B2 (en) | 2013-06-12 | 2017-03-14 | Kaken Pharmaceutical Co., Ltd. | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient |
KR102276644B1 (ko) | 2013-09-04 | 2021-07-13 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조절제로서 유용한 화합물 |
SG11201601682RA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | 1,2,4-oxadiazole derivatives as immunomodulators |
WO2015044900A1 (fr) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Composés immunomodulateurs thérapeutiques |
CA2927392C (fr) | 2013-10-17 | 2021-11-09 | Vertex Pharmaceuticals Incorporated | Inhibiteurs d'adn-pk |
WO2015094912A1 (fr) | 2013-12-17 | 2015-06-25 | Eli Lilly And Company | Composés d'acide diméthylbenzoïque |
HUE035698T2 (en) | 2013-12-17 | 2018-05-28 | Lilly Co Eli | Phenoxyethyl ring amine derivatives and their activity as EP4 receptor modulator |
TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ep4配體之新穎苯并咪唑衍生物 |
TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
CN106572993B (zh) | 2014-05-23 | 2019-07-16 | 卫材R&D管理有限公司 | Ep4拮抗剂在制备治疗癌症的药物中的应用 |
WO2016021742A1 (fr) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr4 |
WO2016054807A1 (fr) | 2014-10-10 | 2016-04-14 | Merck Sharp & Dohme Corp. | Inhibiteurs de la kinase trka, compositions en contenant et méthodes associées |
KR102559499B1 (ko) | 2015-01-09 | 2023-07-25 | 오노 야꾸힝 고교 가부시키가이샤 | 삼환성 스피로 화합물 |
CA2993312A1 (fr) | 2015-07-23 | 2017-01-26 | Takeda Pharmaceutical Company Limited | Derives substitues en 1 de 1,2,3,4-tetrahydro-1,7-naphtyridin-8-amine et leur utilisation comme antagonistes du recepteur ep4 |
JP6860559B2 (ja) | 2015-10-16 | 2021-04-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ep4アンタゴニスト |
-
2018
- 2018-05-17 BR BR112019024114-0A patent/BR112019024114A2/pt unknown
- 2018-05-17 HU HUE18725223A patent/HUE056406T2/hu unknown
- 2018-05-17 KR KR1020197037058A patent/KR102650756B1/ko active IP Right Grant
- 2018-05-17 AU AU2018269667A patent/AU2018269667B2/en active Active
- 2018-05-17 SG SG11201908660R patent/SG11201908660RA/en unknown
- 2018-05-17 DK DK18725223.4T patent/DK3625224T3/da active
- 2018-05-17 RS RS20211259A patent/RS62441B1/sr unknown
- 2018-05-17 EP EP18725223.4A patent/EP3625224B1/fr active Active
- 2018-05-17 CA CA3063637A patent/CA3063637A1/fr active Pending
- 2018-05-17 US US16/614,268 patent/US20200069686A1/en not_active Abandoned
- 2018-05-17 CR CR20190567A patent/CR20190567A/es unknown
- 2018-05-17 CN CN201880031869.9A patent/CN110621666A/zh active Pending
- 2018-05-17 TW TW107116708A patent/TWI768043B/zh active
- 2018-05-17 EA EA201992679A patent/EA039630B1/ru unknown
- 2018-05-17 MA MA49127A patent/MA49127B1/fr unknown
- 2018-05-17 MX MX2019013639A patent/MX2019013639A/es unknown
- 2018-05-17 SI SI201830413T patent/SI3625224T1/sl unknown
- 2018-05-17 JP JP2019563494A patent/JP7065117B2/ja active Active
- 2018-05-17 HR HRP20211532TT patent/HRP20211532T1/hr unknown
- 2018-05-17 PT PT18725223T patent/PT3625224T/pt unknown
- 2018-05-17 AR ARP180101311A patent/AR111806A1/es unknown
- 2018-05-17 WO PCT/EP2018/062865 patent/WO2018210995A1/fr unknown
- 2018-05-17 PE PE2019002413A patent/PE20191787A1/es unknown
- 2018-05-17 ES ES18725223T patent/ES2894124T3/es active Active
- 2018-05-17 LT LTEPPCT/EP2018/062865T patent/LT3625224T/lt unknown
- 2018-05-17 UA UAA201911973A patent/UA124748C2/uk unknown
- 2018-05-17 PL PL18725223T patent/PL3625224T3/pl unknown
-
2019
- 2019-09-30 CO CONC2019/0010804A patent/CO2019010804A2/es unknown
- 2019-11-13 IL IL270616A patent/IL270616B/en unknown
- 2019-11-14 CL CL2019003257A patent/CL2019003257A1/es unknown
- 2019-11-15 PH PH12019502562A patent/PH12019502562A1/en unknown
-
2021
- 2021-09-27 CY CY20211100841T patent/CY1124528T1/el unknown
-
2022
- 2022-11-27 US US18/058,873 patent/US20230165859A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49127A (fr) | Dérivés d'indole n-substitués | |
DK4015003T3 (da) | Forbedret antistof-oligonukleotid-konjugat | |
DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
MA44502A (fr) | Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA44498A (fr) | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
DK3794042T3 (da) | Anti-muc1-exatecet-antistof-lægemiddelkonjugat | |
MA48987A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
MA48943A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA55046A (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
MA54521A (fr) | Dérivés d'oxopyridine substitués | |
MA41341A (fr) | Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
IL267899A (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors | |
DK3768669T3 (da) | Piperazinazaspiroderivater | |
DK4074703T3 (da) | Pyridinyl-(aza)indolsulfonamider | |
MA49006A (fr) | Inhibiteurs d'ip6k | |
MA56043A (fr) | Dérivés hétérocycliques fusionnés | |
DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
DK3870234T3 (da) | Antistoflægemiddelkonjugater omfattende ecteinascidinderivater | |
DK3666787T3 (da) | Antistoflægemiddelkonjugater som inkluderer hemiasterlinderivat | |
DK3796975T3 (da) | Sulfonylaminobenzamidderivater | |
DK3645513T3 (da) | Benzazepinderivater | |
DK3472149T3 (da) | Heterocykliske prolinamidderivater |